DFTX Definium Therapeutics, Inc. - Common Shares
NASDAQ · Voir sur SEC EDGAR ↗ clôture Oct 2, 2026 10-K/10-Q Aoû 6, 2026DFTX Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines
DFTX Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue
La granularité des barres s'adapte à la période sélectionnée — survolez le graphique pour voir l'ouverture/le maximum/le minimum/la clôture d'une barre.
| Date ex-dividende | Division | Type |
|---|---|---|
| 29 août 2022 | 1-for-15 | Inverse |
À propos de Definium Therapeutics, Inc. - Common Shares Présentation de l'entreprise depuis Wikipedia
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
History
MindMed was founded in May 2019 by Stephen Hurst and Jamon Rahn.
MindMed initially focused on developing treatments for opioid withdrawal and opioid use disorder with 18-MC, a non-hallucinogenic molecule based on the psychoactive alkaloid ibogaine. In June 2019, it acquired the 18-MC drug development program, previously funded by the National Institute on Drug Abuse, and in September began to prepare 18-MC for a Phase I FDA clinical trial to enable further clinical trials targeting opioid withdrawal and opioid use disorder.
MindMed was the first psychedelic pharmaceutical company to go public, listing on the Canadian NEO Exchange in March of 2020 through a reverse takeover with the Canadian gold mining company Broadway Gold Mining. It began trading on the Nasdaq as MNMD in April 2021 after being approved for an uplisting from the OTC Markets.
In a press release on June 9, 2021 MindMed announced that Jamon Rahn was stepping down both as the CEO and as a director on the board, to be replaced by then CDO Robert Barrow.
On February 26, 2021, MindMed closed its acquisition of digital health startup HealthMode. In connection with the acquisition, Daniel Karlin MD, CEO of HealthMode, was appointed to the position of CMO of the company.
On August 25, 2022, the first patient was dosed in a phase 2b trial for treatment of MM120 (now DT120) in generalized anxiety disorder (GAD). The study would go on to recruit 198 participants. The majority of trial participants experienced statistically significant improvements in their GAD scores, leading to the approval of multiple phase three human trials.
On January 12, 2026, MindMed rebranded to Definium Therapeutics.
Research
In March 2020, MindMed announced that it had partnered with NYU Langone to launch a clinical training program to train psychiatrists in psychedelic therapies and research to advance and deploy psychedelic medicines. The company committed $5 million to establish the center, which will also explore 18-MC and the use of drugs, including psilocybin-assisted therapy for alcohol use disorder.
In April 2020, the company entered into a long-term partnership with University Hospital Basel's Liechti Lab, gaining rights to more than ten years of the lab's data related to LSD, MDMA, and other psychedelic substances. The development of a novel compound designed to shorten the duration or stop an LSD experience that would allow LSD to be more widely used in a therapeutic environment was subsequently announced. Later that year a clinical trial studying the effects of DMT, the primary psychoactive ingredient in ayahuasca, and clinical trials combining MDMA and LSD were announced. A study to better understand and compare the altered states of consciousness induced by psilocybin and LSD began in August 2020,
and in October a Phase 1 study at the Liechti Lab on the acute dose dependent effects of LSD was completed. The results of the study were published by the American College of Neuropsychopharmacology in the journal Neuropsychopharmacology. In September 2021, further results were presented by Matthias Liechti, head of the Liechti Lab, at the INSIGHT Conference in Berlin. The results included the first clinical evidence on the comparative effects of LSD and psilocybin, stating 100mcg of LSD produced the same acute perceptual effects as a dose of 20 mg of psilocybin in healthy volunteers. Additionally, psilocybin taken after administering antidepressants for two weeks prior, was deemed safe, as well as reduced anxiety and blood pressure without hindering the psychedelic experience.
In December 2020, MindMed entered into an investigator-sponsored study agreement with Maastricht University in the Netherlands. The university provided facilities and personnel for a Phase 1 study to evaluate the effects of two low doses of LSD on mood, sleep and neuroplasticity.
In March 2024, the FDA granted breakthrough therapy designation to MindMed's form of LSD (MM120; now DT120) for the treatment of generalized anxiety disorder. This decision was influenced by a drug trial in which approximately half of the participants experienced significant relief from their symptoms. Positive results in clinical trials against general depression symptoms and generalized anxiety disorder were reported in 2026.
=== Ongoing clinical trials ===
Source : Wikipedia (Anglais), CC BY-SA 4.0 · Voir sur Wikipedia ↗
Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA
Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?
| Métrique | Tendance sur 5 ans | DFTX | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| P/E | -18.2 | · | · | · | |
| P/S | 897.1 | · | · | · | |
| P/B (MRQ) | 5.5 | · | · | · | |
| EV / EBITDA | -20.0 | · | · | · | |
| Price / Cash Flow (Cours / Flux de trésorerie) | -28.1 | · | · | · | |
| EV / Revenue (VE / Chiffre d'affaires) | 807.0 | · | · | · | |
| Price / Tangible Book (Cours / Actif net tangible) | 11.8 | · | · | · |
La médiane des pairs est calculée sur une base standardisée par métrique et peut ne pas toujours correspondre à la base TTM/MRQ indiquée pour cette action.
Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC
| Métrique | Tendance sur 5 ans | DFTX | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| ROA | -49.5%moyenne 5 ans ≈-55.1% | ≈-55.1% | · | · | |
| ROE | -71.0%moyenne 5 ans ≈-64.1% | ≈-64.1% | · | · | |
| ROIC | -44.6% | · | · | · |
Santé financière Dette, liquidité, solvabilité — solidité du bilan
| Métrique | Tendance sur 5 ans | DFTX | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Dette / Capitaux propres (MRQ) | 0.0moyenne 5 ans ≈0.1 | ≈0.1 | · | · | |
| Ratio de liquidité (MRQ) | 6.9moyenne 5 ans ≈7.6 | ≈7.6 | · | · | |
| Quick Ratio (Ratio de liquidité réduite) | 6.2moyenne 5 ans ≈7.4 | ≈7.4 | · | · | |
| Dette à long terme / Capitaux propres (MRQ) | 0.0moyenne 5 ans ≈0.1 | ≈0.1 | · | · | |
| Interest Coverage (Ratio de couverture des intérêts) | -30.3 | · | · | · |
Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans
| Métrique | Tendance sur 5 ans | DFTX | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Revenue YoY (Chiffre d'affaires YoY) | 212.0% | · | · | · |
Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances
Pas encore assez de données fondamentales pour calculer ce groupe de ratios.
valeur · ≈ moyenne 5 ans · médiane du secteur · verdict par rapport à la médiane
Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats
| Période | Rapport | EPS Actual | BPA est. | Surprise |
|---|---|---|---|---|
| 30 juin 2026 | Aoû 6, 2026 | $-1.44 | $-0.56 | -158.2% |
| 31 mars 2026 | Mai 7, 2026 | $-0.71 | $-0.50 | -41.4% |
| 31 décembre 2025 | $-0.50 | $-0.50 | -0.52% | |
| 30 septembre 2025 | $-0.78 | $-0.51 | -52.6% | |
| 30 juin 2025 | $-0.50 | $-0.37 | -34.5% | |
| 31 mars 2025 | $-0.27 | $-0.37 | 27.6% |
Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie
Compte de résultat
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| R&D Expense | $118M | $65M | $52M | $36M | $35M | $19M | |
| SG&A Expense | $49M | $39M | $42M | $30M | $59M | $14M | |
| Operating Expenses | $166M | $104M | $94M | $66M | $94M | $33M | |
| Operating Income | $-166M | $-104M | $-94M | $-66M | $-94M | $-33M | |
| Interest Expense | $5M | $2M | $920.0K | · | · | · | |
| Other Non-op | $-17M | $-5M | $-2M | $10M | $-339.0K | $-907.0K | |
| Pretax Income | $-184M | $-109M | $-96M | $-57M | $-94M | $-34M | |
| Income Tax | $0 | · | · | · | $-1M | · | |
| Net Income | $-184M | $-109M | $-96M | $-57M | $-93M | $-34M | |
| EPS (Basic) | $-2.06 | $-1.54 | $-2.44 | $-1.84 | $-3.40 | · | |
| EPS (Diluted) | $-2.06 | $-1.54 | $-2.44 | $-1.84 | $-3.40 | · | |
| Shares (Basic) | 89,327,608 | 70,461,067 | 39,157,420 | 30,857,463 | 27,377,082 | · | |
| Shares (Diluted) | 89,327,608 | 70,461,067 | 39,157,420 | 30,857,463 | 27,377,082 | · | |
| EBITDA | $-166M | $-104M | $-94M | $-66M | $-94M | · |
Bilan
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $258M | $274M | $100M | $142M | $134M | $80M | |
| Short-term Investments | $154M | $0 | · | · | · | · | |
| Prepaid Expense | $8M | $8M | $4M | $4M | $4M | $1M | |
| Current Assets | $419M | $282M | $104M | $146M | $137M | $82M | |
| Goodwill | $20M | $20M | $20M | $20M | $20M | $0 | |
| Intangibles | · | $0 | $527.0K | $4M | $7M | · | |
| Other Non-current Assets | $862.0K | $613.0K | $224.0K | $331.0K | · | · | |
| Total Assets | $440M | $302M | $125M | $170M | $164M | $82M | |
| Accounts Payable | $5M | $2M | $4M | $2M | $4M | $2M | |
| Accrued Liabilities | $20M | $13M | $12M | $6M | $6M | $986.0K | |
| Current Liabilities | $67M | $39M | $32M | $18M | $10M | $3M | |
| Other Non-current Liabilities | $496.0K | · | $32.0K | $1M | $2M | · | |
| Total Liabilities | $108M | $61M | $46M | $19M | $12M | $6M | |
| Total Debt | $41M | $22M | $14M | · | · | · | |
| Common Stock | · | · | $0 | · | · | · | |
| Retained Earnings | $-583M | $-399M | $-290M | $-194M | $-138M | $-45M | |
| AOCI | $1M | $819.0K | $343.0K | $627.0K | $1M | $284.0K | |
| Stockholders' Equity | $332M | $241M | $78M | $151M | $152M | $76M | |
| Liabilities + Equity | $440M | $302M | $125M | $170M | $164M | $82M | |
| Shares Outstanding | 98,776,265 | 75,100,763 | 41,101,303 | 37,979,136 | 28,126,414 | · |
Flux de trésorerie
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Deferred Tax | · | · | · | · | $-1M | · | |
| Amort. of Intangibles | $0 | $527.0K | $3M | $3M | $3M | $0 | |
| Operating Cash Flow | $-132M | $-79M | $-64M | $-50M | $-46M | $-24M | |
| Investing Cash Flow | $-152M | $0 | · | · | $-297.0K | · | |
| Stock Issued | $0 | $984.0K | $8M | $42M | $82M | $72M | |
| Net Stock Activity | $0 | $984.0K | $8M | $42M | $82M | · | |
| Financing Cash Flow | $267M | $253M | $22M | $59M | $99M | $97M | |
| Net Change in Cash | $-16M | $174M | $-42M | $9M | $53M | $73M | |
| Taxes Paid | $0 | · | · | · | · | · |
Rentabilité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | -2012.6% | -4436.9% | 26143.2% | · | |
| Net Margin | · | · | -2052.6% | -3799.1% | 25915.3% | · | |
| Pretax Margin | · | · | -2052.6% | -3799.1% | 26237.6% | · | |
| EBITDA Margin | · | · | -2012.6% | -4436.9% | 26143.2% | · | |
| ROA | -49.5% | -50.9% | -65.0% | -34.0% | -75.8% | · | |
| ROE | -71.0% | -43.2% | -110.0% | -37.3% | -58.9% | · | |
| ROIC | -44.6% | · | · | · | -61.1% | · |
Liquidité et Solvabilité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 6.3 | 7.2 | 3.2 | 8.2 | 13.2 | · | |
| Quick Ratio | 6.2 | 7.0 | 3.1 | 7.9 | 12.8 | · | |
| Debt / Equity | 0.1 | 0.1 | 0.2 | · | · | · | |
| LT Debt / Equity | 0.1 | 0.1 | 0.2 | · | · | · | |
| Interest Coverage | -30.3 | -45.5 | · | · | · | · |
Efficacité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | -0.0 | · |
Par action
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.36 | $3.21 | $1.90 | $3.97 | · | · | |
| Revenue / Share | · | · | $0.12 | $0.05 | · | · | |
| Cash Flow / Share | $-1.47 | $-1.12 | $-1.64 | $-1.62 | · | · | |
| Cash / Share | $2.61 | $3.65 | $2.43 | $3.74 | · | · | |
| EPS (TTM) | $-2.06 | $-1.54 | $-2.44 | $-1.84 | $-3.40 | · |
Taux de croissance
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | 212.0% | · | · | · |
Valorisation (TTM)
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue TTM | $4M | $4M | $5M | $1M | $-359.0K | · | |
| Net Income TTM | $-184M | $-109M | $-96M | $-57M | $-93M | · | |
| Market Cap | $1.32B | $523M | · | · | · | · | |
| Enterprise Value | $952M | $271M | · | · | · | · | |
| P/E | -6.5 | -4.5 | · | · | · | · | |
| P/S | 321.2 | 126.9 | · | · | · | · | |
| P/B | 4.0 | 2.2 | · | · | · | · | |
| P / Tangible Book | 4.2 | 2.4 | · | · | · | · | |
| P / Cash Flow | -10.1 | -6.6 | · | · | · | · | |
| EV / EBITDA | -5.7 | -2.6 | · | · | · | · | |
| EV / Revenue | 231.1 | 65.8 | · | · | · | · | |
| Earnings Yield | -15.4% | -22.1% | · | · | · | · |
Compte de résultat
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $49M | $41M | $34M | $31M | $30M | $23M | $22M | $17M | $15M | $12M | $12M | $13M | $15M | $13M | $9M | $8M | |
| SG&A Expense | $26M | $18M | $14M | $15M | $11M | $9M | $11M | $8M | $10M | $10M | $11M | $8M | $14M | $8M | $5M | $9M | |
| Operating Expenses | $75M | $59M | $48M | $46M | $41M | $32M | $32M | $25M | $24M | $22M | $22M | $22M | $29M | $21M | $14M | $17M | |
| Operating Income | $-75M | $-59M | $-48M | $-46M | $-41M | $-32M | $-32M | $-25M | $-24M | $-22M | $-22M | $-22M | $-29M | $-21M | $-14M | $-17M | |
| Interest Expense | $1M | $1M | $1M | $1M | $2M | $602.0K | $656.0K | $727.0K | $466.0K | $434.0K | $439.0K | $328.0K | $77.0K | $76.0K | · | · | |
| Other Non-op | $-84M | $-18M | $-3M | $-22M | $-2M | $9M | $-2M | $11M | $19M | $-32M | $-2M | $4M | $54.0K | $-4M | $9M | $498.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $-5M | $-16M | |
| Income Tax | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Net Income | $-159M | $-77M | $-50M | $-67M | $-43M | $-23M | $-35M | $-14M | $-6M | $-54M | $-24M | $-18M | $-29M | $-25M | $-5M | $-16M | |
| EPS (Basic) | $-1.44 | $-0.71 | $-0.51 | $-0.78 | $-0.50 | $-0.27 | $-0.14 | $-0.18 | $-0.08 | $-1.14 | $-0.58 | $-0.45 | $-0.76 | $-0.65 | $-0.02 | $-0.56 | |
| EPS (Diluted) | $-1.44 | $-0.71 | $-0.43 | $-0.78 | $-0.50 | $-0.35 | $0.13 | $-0.27 | $-0.26 | $-1.14 | $-0.58 | $-0.45 | $-0.76 | $-0.65 | $-0.02 | $-0.56 | |
| Shares (Basic) | 110,684,720 | 108,790,941 | · | 85,885,516 | 85,347,677 | 85,067,855 | · | 77,909,441 | 71,912,323 | 47,860,757 | · | 39,720,007 | 38,576,394 | 38,077,251 | · | 29,296,333 | |
| Shares (Diluted) | 110,684,720 | 108,790,941 | · | 85,885,516 | 85,347,677 | 87,091,461 | · | 80,238,688 | 75,304,101 | 47,860,757 | · | 39,720,007 | 38,576,394 | 38,077,251 | · | 29,296,333 | |
| EBITDA | $-75M | $-59M | · | $-46M | $-41M | $-32M | · | $-25M | $-24M | $-22M | · | $-22M | $-29M | $-21M | · | $-17M |
Bilan
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $655M | $263M | $258M | $20M | $33M | $83M | $274M | $295M | $243M | $252M | $100M | $118M | $117M | $129M | $142M | $155M | |
| Short-term Investments | $429M | $111M | $154M | $189M | $150M | $130M | $0 | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $8M | $7M | $8M | $7M | $6M | $9M | $8M | $4M | $5M | $3M | $4M | $2M | $3M | $3M | $4M | $2M | |
| Current Assets | $1.09B | $381M | $419M | $216M | $189M | $222M | $282M | $299M | $248M | $255M | $104M | $120M | $120M | $132M | $146M | $157M | |
| Goodwill | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | |
| Intangibles | · | · | · | · | · | · | · | · | · | · | $527.0K | $1M | $2M | $3M | $4M | $4M | |
| Other Non-current Assets | $880.0K | $812.0K | $862.0K | $1M | $1M | $606.0K | $613.0K | $493.0K | $534.0K | $144.0K | $224.0K | $229.0K | $268.0K | $300.0K | $331.0K | · | |
| Total Assets | $1.11B | $401M | $440M | $237M | $265M | $275M | $302M | $320M | $268M | $276M | $125M | $142M | $142M | $156M | $170M | $181M | |
| Accounts Payable | $7M | $7M | $5M | $8M | $4M | $2M | $2M | $2M | $3M | $8M | $4M | $8M | $9M | $2M | $2M | $824.0K | |
| Accrued Liabilities | $37M | $25M | $20M | $19M | $15M | $11M | $13M | $9M | $8M | $10M | $12M | $10M | $10M | $7M | $6M | $7M | |
| Current Liabilities | $157M | $81M | $67M | $65M | $38M | $30M | $39M | $33M | $42M | $65M | $32M | $31M | $35M | $24M | $18M | $26M | |
| Other Non-current Liabilities | $549.0K | $559.0K | $496.0K | $519.0K | $543.0K | · | · | · | · | $15.0K | $32.0K | $349.0K | $992.0K | $1M | $1M | $1M | |
| Total Liabilities | $194M | $122M | $108M | $106M | $80M | $53M | $61M | $58M | $66M | $79M | $46M | $46M | $36M | $25M | $19M | $27M | |
| Total Debt | $36M | $41M | · | $40M | $41M | $22M | · | $24M | $24M | $14M | · | $14M | · | · | · | · | |
| Common Stock | · | · | · | · | · | · | · | $0 | $0 | · | $0 | · | · | · | · | · | |
| Retained Earnings | $-819M | $-660M | $-583M | $-532M | $-465M | $-422M | $-399M | $-364M | $-350M | $-345M | $-290M | $-266M | $-248M | $-219M | $-194M | $-190M | |
| AOCI | $417.0K | $824.0K | $1M | $1M | $807.0K | $802.0K | $819.0K | $821.0K | $833.0K | $836.0K | $343.0K | $777.0K | $362.0K | $641.0K | $627.0K | $743.0K | |
| Stockholders' Equity | $919M | $279M | $332M | $131M | $185M | $223M | $241M | $262M | $202M | $196M | $78M | $96M | $106M | $130M | $151M | $154M | |
| Liabilities + Equity | $1.11B | $401M | $440M | $237M | $265M | $275M | $302M | $320M | $268M | $276M | $125M | $142M | $142M | $156M | $170M | $181M | |
| Shares Outstanding | 134,365,950 | 104,044,508 | 98,776,265 | 76,774,057 | 75,803,251 | 75,511,375 | 75,100,763 | 81,590,491 | 72,075,076 | 71,163,720 | 41,101,303 | 40,094,708 | 38,807,159 | 38,290,111 | 37,979,136 | 37,541,115 |
Flux de trésorerie
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amort. of Intangibles | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $527.0K | $771.0K | $800.0K | $800.0K | $791.0K | $800.0K | $800.0K | |
| Operating Cash Flow | $-53M | $-43M | $-43M | $-30M | $-30M | $-29M | $-25M | $-17M | $-20M | $-17M | $-21M | $-17M | $-14M | $-13M | $-13M | $-9M | |
| Investing Cash Flow | $-317M | $42M | $35M | $15M | $-40M | $-162M | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Stock Issued | · | · | $0 | $0 | · | · | $0 | $0 | · | · | $3M | $3M | $1M | $583.0K | $730.0K | · | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $583.0K | · | · | |
| Financing Cash Flow | $762M | $5M | $246M | $749.0K | $20M | $1M | $4M | $69M | $11M | $169M | $3M | $17M | $1M | $583.0K | $416.0K | $58M | |
| Net Change in Cash | $393M | $5M | $238M | $-13M | $-49M | $-191M | $-22M | $52M | $-9M | $153M | $-18M | $804.0K | $-13M | $-13M | $-12M | $49M |
Rentabilité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | · | · | · | · | · | -1858.6% | -2226.1% | -1624.8% | · | -4717.5% | |
| Net Margin | · | · | · | · | · | · | · | · | · | · | · | -1541.1% | -2222.0% | -1932.6% | · | -4579.2% | |
| Pretax Margin | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | -4579.2% | |
| EBITDA Margin | · | · | · | · | · | · | · | · | · | · | · | -1858.6% | -2226.1% | -1624.8% | · | -4717.5% | |
| ROA | -23.1% | -22.8% | · | -24.2% | -16.0% | -8.5% | · | -5.9% | -2.9% | -25.2% | · | -11.1% | -21.1% | -16.3% | · | -18.2% | |
| ROE | -28.8% | -30.7% | · | -34.2% | -22.1% | -11.2% | · | -7.6% | -3.8% | -33.3% | · | -14.4% | -25.3% | -18.6% | · | -21.5% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | -11.1% |
Liquidité et Solvabilité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.9 | 4.7 | · | 3.3 | 5.0 | 7.3 | · | 9.0 | 5.9 | 3.9 | · | 3.9 | 3.4 | 5.5 | · | 6.0 | |
| Quick Ratio | 6.9 | 4.6 | · | 3.2 | 4.8 | 7.0 | · | 8.9 | 5.8 | 3.9 | · | 3.8 | 3.3 | 5.4 | · | 5.9 | |
| Debt / Equity | 0.0 | 0.1 | · | 0.3 | 0.2 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | · | · | · | |
| LT Debt / Equity | 0.0 | 0.1 | · | 0.3 | 0.2 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | · | · | · | |
| Interest Coverage | -60.9 | -47.6 | · | -35.8 | -17.5 | -53.4 | · | -34.1 | -52.5 | -51.2 | · | · | · | · | · | · |
Efficacité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Par action
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $6.84 | $2.68 | · | $1.70 | $2.45 | $2.95 | · | $3.21 | $2.80 | $2.75 | · | $2.39 | $2.73 | $3.40 | · | $4.09 | |
| Revenue / Share | · | · | · | · | · | · | · | · | · | · | · | $0.03 | $0.03 | $0.03 | · | $0.01 | |
| Cash Flow / Share | · | $-0.39 | · | · | · | $-0.34 | · | · | · | $-0.35 | · | · | · | $-0.35 | · | · | |
| Cash / Share | $4.88 | $2.52 | · | $0.26 | $0.44 | $1.10 | · | $3.62 | $3.37 | $3.55 | · | $2.94 | $3.01 | $3.38 | · | $4.12 | |
| EPS (TTM) | $-3.36 | $-2.42 | · | $-1.50 | $-0.99 | $-0.75 | · | $-2.25 | $-2.43 | $-2.93 | · | $-1.88 | $-1.99 | $-1.83 | · | $-2.41 |
Valorisation (TTM)
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $5M | $5M | · | $5M | $5M | $5M | · | $5M | $5M | $5M | · | $5M | $4M | $3M | · | $276.0K | |
| Net Income TTM | $-354M | $-238M | · | $-168M | $-115M | $-78M | · | $-98M | $-102M | $-125M | · | $-77M | $-75M | $-63M | · | $-69M | |
| Market Cap | $6.32B | $1.97B | · | $905M | $492M | $442M | · | $464M | $520M | $669M | · | · | · | · | · | · | |
| Enterprise Value | $5.27B | $1.63B | · | $736M | $350M | $251M | · | $193M | $301M | $431M | · | · | · | · | · | · | |
| P/E | -14.0 | -7.8 | · | -7.9 | -6.6 | -7.8 | · | -2.5 | -3.0 | -3.2 | · | · | · | · | · | · | |
| P/S | 1306.4 | 406.5 | · | 187.1 | 101.7 | 91.3 | · | 96.0 | 107.4 | 138.3 | · | · | · | · | · | · | |
| P/B | 6.9 | 7.1 | · | 6.9 | 2.7 | 2.0 | · | 1.8 | 2.6 | 3.4 | · | · | · | · | · | · | |
| P / Tangible Book | 7.0 | 7.6 | · | 8.2 | 3.0 | 2.2 | · | 1.9 | 2.9 | 3.8 | · | · | · | · | · | · | |
| P / Cash Flow | · | -46.1 | · | · | · | -15.0 | · | · | · | -40.3 | · | · | · | · | · | · | |
| EV / Revenue | 1089.9 | 337.7 | · | 152.2 | 72.4 | 52.0 | · | 39.9 | 62.2 | 89.0 | · | · | · | · | · | · | |
| Earnings Yield | -7.1% | -12.8% | · | -12.7% | -15.2% | -12.8% | · | -39.5% | -33.7% | -31.2% | · | · | · | · | · | · |
Période la plus récente à gauche · valeurs nulles affichées comme ·
États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Marge d'exploitation % | · | · | -2012.6% | -4436.9% | 26143.2% |
| Résultat net | $-184M | $-109M | $-96M | $-57M | $-93M |
| BPA dilué | $-2.06 | $-1.54 | $-2.44 | $-1.84 | $-3.40 |
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dette / Capitaux propres | 0.1 | 0.1 | 0.2 | · | · |
| Ratio de liquidité | 6.3 | 7.2 | 3.2 | 8.2 | 13.2 |
| Ratio de liquidité réduite | 6.2 | 7.0 | 3.1 | 7.9 | 12.8 |
Pas assez de données fondamentales pour construire ce relevé pour le moment.
Détenteurs institutionnels (13F) 389 déclarants · $5.1B total · Au 30 septembre 2026
Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.
| Nouvelles positions | Positions clôturées | Augmenté | Diminué | Variation nette des actions |
|---|---|---|---|---|
| 163 | 28 | 120 | 65 | · |
Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée. Variation par rapport au trimestre précédent non affichée : la couverture des déclarants diffère trop entre ces deux trimestres pour une comparaison fiable.
| Institution | Valeur | Actions | % de 13F suivies | Type |
|---|---|---|---|---|
| BlackRock, Inc. | $528 392 511 | 11 232 834 | 10,30% | Actions |
| Avoro Capital Advisors LLC | $338 165 292 | 7 188 888 | 6,59% | Actions |
| Driehaus Capital Management LLC | $322 001 783 | 6 845 276 | 6,28% | Actions |
| Capital World Investors | $252 497 690 | 5 367 723 | 4,92% | Actions |
| FMR LLC | $223 577 402 | 4 752 921 | 4,36% | Actions |
| GEODE CAPITAL MANAGEMENT, LLC | $171 482 802 | 3 644 813 | 3,34% | Actions |
| STATE STREET CORP | $144 195 946 | 3 065 390 | 2,81% | Actions |
| Capital International Investors | $139 398 806 | 2 963 410 | 2,72% | Actions |
| Octagon Capital Advisors LP | $138 768 000 | 2 950 000 | 2,71% | Actions |
| WELLINGTON MANAGEMENT GROUP LLP | $138 755 487 | 2 949 734 | 2,71% | Actions |
| Deep Track Capital, LP | $129 360 000 | 2 750 000 | 2,52% | Actions |
| Commodore Capital LP | $94 080 000 | 2 000 000 | 1,83% | Actions |
| GOLDMAN SACHS GROUP INC | $84 712 079 | 1 800 852 | 1,65% | Actions |
| CITADEL ADVISORS LLC | $79 431 133 | 1 688 587 | 1,55% | Actions |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $77 541 959 | 1 648 426 | 1,51% | Actions |
| RA CAPITAL MANAGEMENT, L.P. | $70 560 000 | 1 500 000 | 1,38% | Actions |
| VANGUARD CAPITAL MANAGEMENT LLC | $69 922 796 | 1 486 454 | 1,36% | Actions |
| JANUS HENDERSON GROUP PLC | $67 226 955 | 3 556 041 | 1,31% | Actions |
| Siren, L.L.C. | $66 772 951 | 1 419 493 | 1,30% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $65 216 256 | 1 386 400 | 1,27% | Option d'achat |
| MARSHALL WACE, LLP | $61 102 420 | 1 298 946 | 1,19% | Actions |
| NORTHERN TRUST CORP | $55 000 956 | 1 169 238 | 1,07% | Actions |
| AMERIPRISE FINANCIAL INC | $54 018 997 | 1 148 363 | 1,05% | Actions |
| Nuveen, LLC | $51 993 971 | 1 105 314 | 1,01% | Actions |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $50 971 415 | 1 083 576 | 0,99% | Actions |
| Woodline Partners LP | $47 211 273 | 1 003 641 | 0,92% | Actions |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $47 040 000 | 1 000 000 | 0,92% | Actions |
| Boxer Capital Management, LLC | $46 969 440 | 998 500 | 0,92% | Actions |
| TWO SIGMA INVESTMENTS, LP | $43 362 319 | 921 818 | 0,85% | Actions |
| Balyasny Asset Management L.P. | $42 217 365 | 897 478 | 0,82% | Actions |
| VANGUARD FIDUCIARY TRUST CO | $38 934 679 | 827 693 | 0,76% | Actions |
| Holocene Advisors, LP | $37 470 841 | 796 574 | 0,73% | Actions |
| AWM Investment Company, Inc. | $36 916 992 | 784 800 | 0,72% | Actions |
| Bank of New York Mellon Corp | $36 562 821 | 777 271 | 0,71% | Actions |
| Polar Capital Holdings Plc | $36 561 981 | 777 253 | 0,71% | Actions |
| ALLIANCEBERNSTEIN L.P. | $34 082 124 | 1 803 287 | 0,66% | Actions |
| EVENTIDE ASSET MANAGEMENT, LLC | $33 398 400 | 710 000 | 0,65% | Actions |
| NEUBERGER BERMAN GROUP LLC | $32 341 834 | 687 539 | 0,63% | Actions |
| Qube Research & Technologies Ltd | $32 123 663 | 682 901 | 0,63% | Actions |
| Candriam S.C.A. | $28 874 744 | 614 425 | 0,56% | Actions |
| ArrowMark Colorado Holdings LLC | $26 533 806 | 564 069 | 0,52% | Actions |
| Catalio Capital Management, LP | $26 468 091 | 562 672 | 0,52% | Actions |
| Blackstone Inc. | $26 418 228 | 561 612 | 0,52% | Actions |
| Integral Health Asset Management, LLC | $25 872 000 | 550 000 | 0,50% | Actions |
| BAMCO INC /NY/ | $24 465 880 | 520 108 | 0,48% | Actions |
| UBS Group AG | $23 494 928 | 499 467 | 0,46% | Actions |
| FRANKLIN RESOURCES INC | $22 871 742 | 486 219 | 0,45% | Actions |
| Point72 Asset Management, L.P. | $22 766 419 | 483 980 | 0,44% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $22 155 840 | 471 000 | 0,43% | Option de vente |
| Ensign Peak Advisors, Inc | $21 925 626 | 466 106 | 0,43% | Actions |
Initiés de la société 16 initiés · 9 dirigeants · 9 administrateurs
| Dirigeant | Rôle | Dernière activité | Actions détenues | Achats 12m | Ventes 12m | Net 12m |
|---|---|---|---|---|---|---|
| Robert Barrow | Chief Executive Officer | 25 septembre 2026 S | 2 213 090 | 0 | 5 | $-3 981 146 |
| Brandi Roberts | Chief Financial Officer | 25 septembre 2026 S | 394 528 | 0 | 2 | $-259 172 |
| Schond L. Greenway | Chief Financial Officer | 25 mars 2024 F | 211 057 | 0 | 0 | $0 |
| Miri Halperin Wernli | Executive President | 21 août 2024 M | 202 405 | 0 | 0 | $0 |
| Dan Karlin | Chief Medical Officer | 25 septembre 2026 S | 792 846 | 0 | 4 | $-1 070 502 |
| Matthew T. Wiley | Chief Commercial Officer | 25 septembre 2026 S | 359 036 | 0 | 2 | $-242 358 |
| Mark Sullivan | Chief Legal Officer | 25 septembre 2026 S | 494 228 | 0 | 4 | $-1 445 540 |
| Carrie Liao | Chief Accounting Officer | 25 mars 2025 S | 144 923 | 0 | 0 | $0 |
| Cynthia W. Hu | Chief Legal Officer&Secretary | 24 mars 2022 A | 1 200 000 | 0 | 0 | $0 |
| Andreas Krebs | Administrateur | 18 septembre 2026 M | 21 402 | 0 | 0 | $0 |
| Carol A Vallone | Administrateur | 18 septembre 2026 M | 22 296 | 0 | 0 | $0 |
| Roger Adsett | Administrateur | 11 juin 2026 A | 3 555 | 0 | 0 | $0 |
| Roger Crystal | Administrateur | 11 juin 2026 A | 24 289 | 0 | 0 | $0 |
| Suzanne Louise Bruhn | Administrateur | 11 juin 2026 A | 24 289 | 0 | 0 | $0 |
| David W Gryska | Administrateur | 11 juin 2026 A | 19 900 | 0 | 0 | $0 |
| Brigid Makes | Administrateur | 1 juin 2022 A | 158 706 | 0 | 0 | $0 |
Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché
Détention d'ETF Détenu par 22 ETFs
Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.
| Fonds | Poids | Unités | Au | Source |
|---|---|---|---|---|
| PILL · Direxion Shares ETF Trust | 2,13% | 10 109 NS | 31 juillet 2026 | N-PORT |
| BBC · ETFis Series Trust I | 1,18% | 12 558 NS | 31 juillet 2026 | N-PORT |
| IHE · iShares Trust | 1,12% | 479 902 SH | 11 septembre 2026 | Quotidien |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,36% | 139 235 SH | 19 août 2026 | Quotidien |
| IBB · iShares Trust | 0,36% | 974 814 SH | 11 septembre 2026 | Quotidien |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,34% | 9 504 SH | 2 octobre 2026 | Quotidien |
| IWO · iShares Trust | 0,32% | 1 221 670 SH | 11 septembre 2026 | Quotidien |
| NUSC · Nushares ETF Trust | 0,31% | 90 473 NS | 31 juillet 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,20% | 86 461 SH | 19 août 2026 | Quotidien |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,19% | 748 959 SH | 19 août 2026 | Quotidien |
| RSSL · Global X Funds | 0,18% | 62 307 NS | 31 juillet 2026 | N-PORT |
| IWM · iShares Trust | 0,16% | 3 329 545 SH | 11 septembre 2026 | Quotidien |
| ESML · iShares Trust | 0,10% | 73 991 SH | 11 septembre 2026 | Quotidien |
| VHT · VANGUARD WORLD FUND | 0,08% | 331 180 SH | 19 août 2026 | Quotidien |
| VXF · VANGUARD INDEX FUNDS | 0,07% | 1 486 454 SH | 19 août 2026 | Quotidien |
| FHLC · FIDELITY COVINGTON TRUST | 0,07% | 52 257 NS | 31 juillet 2026 | N-PORT |
| FBCG · FIDELITY COVINGTON TRUST | 0,06% | 103 206 NS | 31 juillet 2026 | N-PORT |
| WSML · iShares Trust | 0,04% | 6 834 SH | 11 septembre 2026 | Quotidien |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,03% | 17 940 SH | 2 octobre 2026 | Quotidien |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 10 703 SH | 19 août 2026 | Quotidien |
| IWV · iShares Trust | 0,01% | 34 866 SH | 10 septembre 2026 | Quotidien |
| ITOT · iShares Trust | 0,01% | 161 931 SH | 11 septembre 2026 | Quotidien |
DFTX Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse
Objectif de cours à 12 mois
17 analystes · 2026-10-04Objectif moyen $71.65 +91,6%
Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur
Base F.A., prix à la clôture de la dernière fin d'exercice de chaque société.
| Ticker | Capitalisation Boursière | P/E | Revenus Année/Année | Marge Nette | ROE | Marge Brute |
|---|---|---|---|---|---|---|
| DFTX | $1.32B | -6.5 | 212.0% | · | -71.0% | · |
| BLTE | $6.29B | -69.2 | · | · | -16.9% | · |
| AMRX | · | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| LGND | $3.74B | 30.8 | 60.4% | 46.4% | 13.5% | · |
| MANE | · | · | · | · | 82.6% | · |
| EWTX | $2.64B | -15.2 | · | · | -30.2% | · |
| INDV | · | 21.9 | 4.3% | 17.0% | -118.3% | 80.2% |
| OGN | $1.87B | 10.0 | -2.9% | 3.0% | 25.2% | 53.3% |
| AMLX | $1.33B | -7.9 | -77.1% | · | -61.2% | · |
| LLY | · | 46.8 | 44.7% | 31.7% | 101.2% | · |
Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets
Choisissez les indicateurs qui vous importent — cliquez sur le + à côté de n'importe quelle ligne dans les Fondamentaux complets ci-dessus.
Votre sélection est enregistrée et vous suit sur tous les tickers.